LCT waiting for minister
Thursday, 26 June, 2008
Living Cell Technologies (ASX: LCT) expects to hear on or after August 8 whether it can proceed with a New Zealand trial of its encapsulated porcine islet cell product, DiabeCell.
The New Zealand Minister for Health, David Cunliffe, has sought independent advice from the country's National Health Committee (NHC) on whether to authorise the phase I/IIa clinical trial.
LCT said in a statement it had already received approval from NZ regulatory bodies such as the regional ethics committee, the Gene Technology Advisory Committee and International Accreditation New Zealand.
It has also received approval from Medsafe, the regulatory body that approved the manufacture for human use of encapsulated porcine cells.
LCT is currently running a small clinical trial at the Sklifosovsky Institute in Moscow.
Exclusive colostrum intake may reduce risk of food allergies
Newborns who are exclusively fed colostrum in the first 72 hours following birth are five times...
Sunscreen and supplements can lower your vitamin D levels
People who use SPF50+ sunscreen daily are more likely to be vitamin D deficient, while taking...
Low-dose drug prevents diabetes progression in young people
A low dose of the immunomodulatory drug anti-thymocyte globulin (ATG) appears safe and effective...
